Current research into retatrutide, a dual agonist for GLP-1 and GIP receptors, are demonstrating encouraging effects in managing obesity and diabetes second-type diabetes. Initial evidence suggest a distinct mechanism https://shopretatrutidepeptide.com/2026/03/12/what-is-retatrutide-peptide/